


## PHARMACEUTICAL 2020

## Viking Therapeutics Inc. Rank 11 of 358







## PHARMACEUTICAL 2020



## Viking Therapeutics Inc. Rank 11 of 358

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Viking Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 310%, being 273% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	283,501
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,777
Liabilities, Non-Current	360
Other Assets	755
Other Compr. Net Income	435
Other Expenses	0
Other Liabilities	0
Other Net Income	6,908
Other Revenues	0
Property and Equipment	0
Research and Development	23,559
Selling, General and Administrative Expense	9,128

Output Variable	Value in 1000 USD
Assets	284,256
Liabilities	7,137
Expenses	32,687
Revenues	0
Stockholders Equity	277,119
Net Income	-25,779
Comprehensive Net Income	-25,562
Economic Capital Ratio	310%

